(Grant DE 1431/10-1)
Semin Cutan Med Surg 1997
Multiple sclerosis, an autoimmune demyelinating disease of the central nervous system, may benefit from the anti-inflammatory and neuroprotective properties of GLP-1RAs.137 Clinical observations indicate a reduced risk of multiple sclerosis relapse among T2DM patients treated with GLP-1RAs, potentially attributable to metabolic improvements and anti-inflammatory effects.138 Experimental autoimmune encephalomyelitis models have demonstrated that liraglutide attenuates central nervous system inflammation and demyelination.139 Additionally, GLP-1RAs have been shown to enhance motor function and prolong survival in amyotrophic lateral sclerosis models, reduce neuronal degeneration, improve behavioral outcomes in Huntingtons disease models, and confer neuroprotection following traumatic brain injury and stroke by mitigating inflammation, reducing cerebral edema, and promoting neurological recovery.129 GLP-1RAs and Mental Health Worldwide, approximately 35 million individuals suffer from substance use disorders, with an estimated 280 million affected by alcohol use disorder (AUD).140 Tobacco use is prevalent in approximately one-quarter of the global adult population.141 AUD is linked to elevated mortality rates due to medical complications, injuries,142 and suicide.143 AUDs ramifications extend beyond the afflicted individual, impacting family members144 and society at large
Performance further improved when analyses were restricted to fatal CVD events (0.88-0.93, 0.82-0.92, and 0.83-0.87, respectively) [15]
Pfizer acquired obesity drug developer Metsera last year for $10 billion, securing a competitive obesity treatment pipeline including the injectable GLP-1 receptor agonist MET 097i, the amylin analog MET 233i, oral GLP-1 candidate substances, and preclinical assets based on nutrient-stimulating hormones
/assets/images/provider/photos/2774234.jpeg)
